Verition Fund Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Verition Fund Management’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-20,000	Closed	-$6K	–	3041
2022 Q3	$6K	Hold	20,000	–	–	﹤0.01%	2929
2022 Q2	$7K	Hold	20,000	–	–	﹤0.01%	2256
2022 Q1	$13K	Hold	20,000	–	–	﹤0.01%	2640
2021 Q4	$26K	Hold	20,000	–	–	﹤0.01%	2466
2021 Q3	$43K	Hold	20,000	–	–	﹤0.01%	1789
2021 Q2	$55K	Sell	20,000 -234,684	-92%	-$583K	﹤0.01%	1796
2021 Q1	$665K	Hold	254,684	–	–	0.01%	738
2020 Q4	$708K	Buy	254,684 +244,684	+2,447%	+$712K	0.01%	573
2020 Q3	$46K	Buy	+10,000	New	+$33K	﹤0.01%	1007

Other funds holding SIOX

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

TVWM

Tower View Wealth Management Shorewood, Wisconsin $227M AUM 41.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Verition Fund Management's SIOX Position: Q4 2022 in Review

Verition Fund Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2022, closing a stake of 20,000 shares — an estimated $6K sold.

Verition Fund Management first reported a position in SIOX in Q3 2020 and held it in 9 quarters. The position peaked at $708K in Q4 2020. 37 funds tracked by Wall St. Rank hold SIOX as of Q4 2022.

Verition Fund Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Verition Fund Management sold 20,000 Sio Gene Therapies Inc. Common Stock shares in Q4 2022, an estimated $6K.
Verition Fund Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2020 and held it in 9 quarters.
Verition Fund Management's Sio Gene Therapies Inc. Common Stock position peaked at $708K in Q4 2020.
37 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2022.

Based on Verition Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.